LO31 Stock Overview

Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. More details

LO31 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	4/6
Past Performance	1/6
Financial Health	5/6
Dividends	3/6

Rewards

Earnings are forecast to grow 21.13% per year

Risk Analysis

Shares are highly illiquid

Large one-off items impacting financial results

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Lonza Group AG Competitors

Sartorius

XTRA:SRT3

€14.4b

SCHOTT Pharma KGaA

XTRA:1SXP

€3.5b

Gerresheimer

XTRA:GXI

€2.6b

Merck KGaA

XTRA:MRK

€57.1b

Price History & Performance

Summary of share price highs, lows and changes for Lonza Group
Historical stock prices
Current Share Price	CHF 5.60
52 Week High	CHF 5.80
52 Week Low	CHF 5.20
Beta	0.68
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-3.45%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	LO31	DE Life Sciences	DE Market
7D	0%	-1.0%	-1.3%
1Y	n/a	-17.5%	13.1%

Return vs Industry: Insufficient data to determine how LO31 performed against the German Life Sciences industry.

Return vs Market: Insufficient data to determine how LO31 performed against the German Market.

Price Volatility

Is LO31's price volatile compared to industry and market?
LO31 volatility
LO31 Average Weekly Movement	n/a
Life Sciences Industry Average Movement	6.7%
Market Average Movement	5.4%
10% most volatile stocks in DE Market	12.1%
10% least volatile stocks in DE Market	2.8%

Stable Share Price: LO31's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine LO31's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1897	18,686	Wolfgang Wienand	www.lonza.com

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing.

Lonza Group AG Fundamentals Summary

How do Lonza Group's earnings and revenue compare to its market cap?
LO31 fundamental statistics
Market cap	€42.96b
Earnings (TTM)	€665.57m
Revenue (TTM)	€6.88b

64.5x

P/E Ratio

6.2x

P/S Ratio

Is LO31 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LO31 income statement (TTM)
Revenue	CHF 6.57b
Cost of Revenue	CHF 4.16b
Gross Profit	CHF 2.41b
Other Expenses	CHF 1.78b
Earnings	CHF 636.00m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Apr 03, 2025

Earnings per share (EPS)	8.81
Gross Margin	36.67%
Net Profit Margin	9.67%
Debt/Equity Ratio	50.2%

How did LO31 perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

45%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/24 09:53
End of Day Share Price	2025/03/21 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lonza Group AG is covered by 47 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Martin Schnee	AlphaValue
Charles Pitman-King	Barclays
Sebastian Bray	Berenberg